Biosputnik presents first data for it's ongoing development program in rare lung disease Lymphangioleiomyomatosis. /  by Stella Baehr

We are happy to announce that our abstract submission was selected for a poster presentation at the Annual International LAM Research Conference and LAMposium. We are excited to be able to share our data not just with the LAM scientific community, but with patients attending the symposium as well.

// The Symposium was held September 8 – 11, 2022 in Chicago. Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R41HL156767. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Myelo001 /  by Dirk Pleimes

Myelo001+Cell.jpg

Myelo001 is a orally bioavailable small molecule developed by Myelo Therapeutics GmbH, Berlin, Germany. BioSputnik LLC works with Myelo Therapeutics GmbH to develop this molecule for the indication of chemotherapy-induced myelosuppression (CIM), radiation-induced myelosuppression (RIM), as well as acute radiation syndrome (ARS).